Published on
Apr 10, 2026
Pennsylvania Medicaid stopped covering GLP-1s for obesity this year, but it's not all savings
Listen to article • 0:00 min Pennsylvania’s Medicaid spending for GLP-1s like Ozempic, Wegovy, and Zepbound exploded to an estimated $1.3 billion last year — from $233 million in 2022, the year before Medicaid started covering the drugs for obesity. That …
Source:
The Philadelphia Inquirer - Pennsylvania
-
Center-left
